Cell therapy (NK cells) · Kills target cells, directed at CD19 · developed by Fate Therapeutics
FT522 is an allogeneic, iPSC-derived natural killer cell product engineered to express an anti-CD19 chimeric antigen receptor, a high-affinity CD16 Fc receptor, an IL-15 fusion, and an alloimmune defense receptor targeting 4-1BB, with CD38 expression eliminated. It kills CD19-expressing tumor cells and is being studied in relapsed or refractory B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05950334 | Phase 1 | Relapsed/Refractory B-Cell Lymphoma | Completed | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory B-Cell Lymphoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →